Zogenix, Inc. (ZGNX): Price and Financial Metrics


Zogenix, Inc. (ZGNX): $15.49

-0.23 (-1.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZGNX POWR Grades


  • ZGNX scores best on the Growth dimension, with a Growth rank ahead of 75.61% of US stocks.
  • ZGNX's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • ZGNX's current lowest rank is in the Sentiment metric (where it is better than 2.52% of US stocks).

ZGNX Stock Summary

  • ZGNX's price/sales ratio is 20.05; that's higher than the P/S ratio of 90.27% of US stocks.
  • With a year-over-year growth in debt of 1,203.14%, Zogenix Inc's debt growth rate surpasses 98.68% of about US stocks.
  • As for revenue growth, note that ZGNX's revenue has grown 801.96% over the past 12 months; that beats the revenue growth of 98.8% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Zogenix Inc are CLGN, LQDA, RYTM, DCPH, and VSTM.
  • ZGNX's SEC filings can be seen here. And to visit Zogenix Inc's official web site, go to www.zogenix.com.

ZGNX Valuation Summary

  • ZGNX's price/earnings ratio is -3.4; this is 109.32% lower than that of the median Healthcare stock.
  • ZGNX's price/sales ratio has moved up 10.7 over the prior 130 months.
  • Over the past 130 months, ZGNX's EV/EBIT ratio has gone down 1.

Below are key valuation metrics over time for ZGNX.

Stock Date P/S P/B P/E EV/EBIT
ZGNX 2021-08-31 18.9 3.0 -3.4 -3.7
ZGNX 2021-08-30 18.6 3.0 -3.3 -3.6
ZGNX 2021-08-27 18.6 3.0 -3.3 -3.6
ZGNX 2021-08-26 18.2 2.9 -3.3 -3.5
ZGNX 2021-08-25 18.5 3.0 -3.3 -3.6
ZGNX 2021-08-24 18.2 2.9 -3.3 -3.5

ZGNX Growth Metrics

  • The 5 year net cashflow from operations growth rate now stands at -130.34%.
  • Its 2 year net income to common stockholders growth rate is now at -202.23%.
  • Its 2 year cash and equivalents growth rate is now at -0.73%.
ZGNX's revenue has moved up $7,835,000 over the prior 70 months.

The table below shows ZGNX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 43.835 -180.539 -244.785
2021-03-31 26.078 -168.898 -239.213
2020-12-31 13.643 -167.531 -209.383
2020-09-30 7.09 -164.017 -195.273
2020-06-30 4.86 -153.562 -425.662
2020-03-31 4.897 -139.183 -410.101

ZGNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZGNX has a Quality Grade of C, ranking ahead of 61.21% of graded US stocks.
  • ZGNX's asset turnover comes in at 0.071 -- ranking 291st of 677 Pharmaceutical Products stocks.
  • ARMP, BTX, and PRTK are the stocks whose asset turnover ratios are most correlated with ZGNX.

The table below shows ZGNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.944 -0.554
2021-03-31 0.042 0.953 -0.656
2020-12-31 0.022 0.960 -0.759
2020-09-30 0.013 0.980 -0.970
2020-06-30 0.010 1.000 -2.411
2020-03-31 0.010 1.000 -1.828

ZGNX Price Target

For more insight on analysts targets of ZGNX, see our ZGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $41.00 Average Broker Recommendation 1.38 (Strong Buy)

ZGNX Stock Price Chart Interactive Chart >

Price chart for ZGNX

ZGNX Price/Volume Stats

Current price $15.49 52-week high $23.69
Prev. close $15.72 52-week low $13.01
Day low $15.48 Volume 357,500
Day high $16.03 Avg. volume 833,103
50-day MA $15.20 Dividend yield N/A
200-day MA $18.37 Market Cap 865.86M

Zogenix, Inc. (ZGNX) Company Bio


Zogenix develops and commercializes therapies for the treatment of central nervous system disorders. The company was founded in 2006 and is based in San Diego, California.


ZGNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ZGNX Latest Social Stream


Loading social stream, please wait...

View Full ZGNX Social Stream

Latest ZGNX News From Around the Web

Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.

Zogenix (ZGNX) Moves 6.2% Higher: Will This Strength Last?

Zogenix (ZGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | September 22, 2021

Dravet Syndrome Treatment Market Aims to Expand at Double-Digit Growth Rate | Zogenix, GW Pharmaceuticals

To make market focusing on and deals exercises simpler, this Dravet Syndrome Treatment market report focuses on key market fragments. It will likewise assist you with drawing in various sorts of clients by advancing significant strategies. This Dravet Syndrome Treatment

OpenPR | September 9, 2021

5 Stocks With 195% to 467% Upside, According to Wall Street

If the high-water price target for each of the following five stocks were to come to fruition, shareholders would be looking at gains ranging from a low of 195% to as much as 467%. If you're "only" looking to triple your money, analyst Amit Dayal of H.C. Wainwright would suggest putting it to work in hydrogen fuel-cell solutions company Plug Power (NASDAQ: PLUG). Dayal's price target of $78 implies a cool 195% upside from where its shares closed this past weekend.

Yahoo | September 8, 2021

3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023

Since the end of the Great Recession in 2009, growth stocks have thrived. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of FactSet, implies a revenue increase ranging from a low of 1,185% (yes, a low of 1,185%) to a high of 12,629%, compared to 2020 sales. Arguably the best-known name on this list is biotech Moderna (NASDAQ: MRNA).

Yahoo | September 3, 2021

Global Dravet Syndrome (DS) Market Analysis, Scope and Forecast By 2021-2027. The IBI Updates I Top key players-Ovid Therapeutics/Takeda, PTC Therapeutics and Zogenix & Others

The research provided by Infinity Business Insights provides a thorough explanation of the disease as well as DS market trends in several locations. It examines multiple studies and the perspectives of important opinion leaders to assist identify the reasons of

OpenPR | September 2, 2021

Read More 'ZGNX' Stories Here

ZGNX Price Returns

1-mo 8.40%
3-mo -17.17%
6-mo -16.34%
1-year -11.49%
3-year -68.80%
5-year 49.66%
YTD -22.51%
2020 -61.65%
2019 42.98%
2018 -8.96%
2017 229.63%
2016 -17.57%

Continue Researching ZGNX

Want to see what other sources are saying about Zogenix Inc's financials and stock price? Try the links below:

Zogenix Inc (ZGNX) Stock Price | Nasdaq
Zogenix Inc (ZGNX) Stock Quote, History and News - Yahoo Finance
Zogenix Inc (ZGNX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9373 seconds.